UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Automated solid-phase extraction method for measuring urinary polycyclic aromatic hydrocarbon metabolites in human biomonitoring using isotope-dilution gas chromatography high-resolution mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006-05, Vol.835 (1), p.47-54

2006

Volltextzugriff (PDF)

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Annals of oncology, 2018-10, Vol.29, p.viii713-viii713

2018

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Annals of oncology, 2018-11, Vol.29, p.ix175-ix175

2018

Volltextzugriff (PDF)

P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S578-S578

2019

Volltextzugriff (PDF)

Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)

Annals of oncology, 2018-10, Vol.29, p.viii547-viii547

2018

Volltextzugriff (PDF)

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Annals of oncology, 2018-10, Vol.29, p.viii400-viii401

2018

Volltextzugriff (PDF)

Immunization status and sociodemographic characteristics: the mediating role of beliefs, attitudes, and perceived control

American journal of public health (1971), 1998-12, Vol.88 (12), p.1821-1826

1998

Volltextzugriff (PDF)

Developing a Deactivation Guideline for Patients With Implantable Cardioverter Defibrillators Reaching End of Life: Our Experience and Findings

Canadian journal of cardiology, 2016-10, Vol.32 (10), p.S324-S325

2016

Volltextzugriff (PDF)

“Tick talk” Before the “Block”: The Cardiac Manifestations of Lyme Disease

Canadian journal of cardiology, 2016-10, Vol.32 (10), p.S321-S321

2016

Volltextzugriff (PDF)

CARDIAC RHYTHM DEVICES AND END OF LIFE CARE: DEVELOPMENT OF AN EDUCATIONAL TOOL FOR NURSE EDUCATORS AND INTERPROFESSIONALS

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.S370-S370

2014

Volltextzugriff (PDF)

Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation

Molecular and Cellular Biology, 1998-09, Vol.18 (9), p.5208-5218

1998

Volltextzugriff (PDF)

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Clinical cancer research, 2020-01, Vol.26 (2), p.439-449

2020

Volltextzugriff (PDF)

P47.15 A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1103-S1103

2021

Volltextzugriff (PDF)

P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S585-S586

2018

Volltextzugriff (PDF)

MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S21-S21

2021

Volltextzugriff (PDF)

P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S258-S258

2021

Volltextzugriff (PDF)

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Annals of oncology, 2022-03, Vol.33, p.S19-S20

2022

Volltextzugriff (PDF)

533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

Annals of oncology, 2021-09, Vol.32, p.S598-S599

2021

Volltextzugriff (PDF)

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Annals of oncology, 2021-09, Vol.32, p.S949-S949

2021

Volltextzugriff (PDF)

THE SHOCKING REALITY - ADOLESCENTS LIVING WITH HYPERTROPHIC CARDIOMYOPATHY

Canadian journal of cardiology, 2019-10, Vol.35 (10), p.S203-S204

2019

Volltextzugriff (PDF)

P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy Decortication

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S758-S759

2019

Volltextzugriff (PDF)

P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1039-S1040

2021

Volltextzugriff (PDF)

HEALING A BROKEN HEART - AN IN-DEPTH LOOK AT TAKOTSUBO CARDIOMYOPATHY

Canadian journal of cardiology, 2018-10, Vol.34 (10), p.S203-S203

2018

Volltextzugriff (PDF)

GOING VIRAL - A CASE STUDY ON DILATED CARDIOMYOPATHY

Canadian journal of cardiology, 2018-10, Vol.34 (10), p.S209-S209

2018

Volltextzugriff (PDF)

1 – 25 von 859

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(772)
Mit Volltextzugriff
(667)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Automated solid-phase extraction method for measuring urinary polycyclic aromatic hydrocarbon metabolites in human biomonitoring using isotope-dilution gas chromatography high-resolution mass spectrometry

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer

Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Immunization status and sociodemographic characteristics: the mediating role of beliefs, attitudes, and perceived control

Developing a Deactivation Guideline for Patients With Implantable Cardioverter Defibrillators Reaching End of Life: Our Experience and Findings

“Tick talk” Before the “Block”: The Cardiac Manifestations of Lyme Disease

CARDIAC RHYTHM DEVICES AND END OF LIFE CARE: DEVELOPMENT OF AN EDUCATIONAL TOOL FOR NURSE EDUCATORS AND INTERPROFESSIONALS

Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

P47.15 A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results

P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy

P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

THE SHOCKING REALITY - ADOLESCENTS LIVING WITH HYPERTROPHIC CARDIOMYOPATHY

P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy Decortication

P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

HEALING A BROKEN HEART - AN IN-DEPTH LOOK AT TAKOTSUBO CARDIOMYOPATHY

GOING VIRAL - A CASE STUDY ON DILATED CARDIOMYOPATHY

Suchergebnisse filtern